FDA review: Long-acting asthma drugs pose serious risks
The FDA should revoke clearance for asthma drugs known as long-acting beta agonists for children in light of clinical evidence linking them to a higher risk of asthma attacks and death, according to a review from the agency's drug-safety personnel. The FDA plans to gather a panel of outside experts this week to evaluate the safety of AstraZeneca's Symbicort, Novartis AG's Foradil and GlaxoSmithKline's Advair and Serevent.
Reuters | 12/05
This story published in FMI Pharmacy dailyLead on 12/08/2008
More from SmartBrief:
FDA: Most drugmakers meeting timelines of postmarketing studies
Wednesday, September 9, 2009
Study: Minority children don't take asthma meds as regularly as whites
Thursday, October 15, 2009
Novartis' H1N1 vaccine may not arrive until next year, CEO says
Friday, October 23, 2009
Get stories like these delivered daily for FREE:
|
FMI Pharmacy dailyLead
Designed specifically for pharmacy professionals, FMI Pharmacy dailyLead is a FREE, daily e-mail newsletter. It provides the latest news in the pharmacy arena. Learn more |
|